TY - JOUR
T1 - Selective serotonin reuptake inhibitor treatment and risk of fractures
T2 - Ameta-analysis of cohort and case-control studies
AU - Wu, Q.
AU - Bencaz, A. F.
AU - Hentz, J. G.
AU - Crowell, M. D.
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Summary Studies on use of selective serotonin reuptake inhibitors (SSRIs) and risk of fracture have yielded inconsistent results. This meta-analysis, which pooled results from 13 qualifying cohort and case-control studies, found that SSRIs were associated with a significantly increased risk of fractures. Introduction This study was conducted to assess whether people who take SSRIs are at an increased risk of fracture. Methods We conducted a meta-analysis of observational studies. Relevant studies published by February 2010 were identified through literature searches using MEDLINE (from 1966), EMBASE (from 1988), PsycINFO (from 1806), and manual searching of reference lists. Only cohort or case-control studies that examined the association of SSRIs and risk of fracture and bone loss were included. Data were abstracted independently by two investigators using a standardized protocol; disagreements were resolved by consensus. Random effects models were used for pooled analysis due to heterogeneity in the studies. Results Thirteen studies met inclusion criteria. Overall, SSRI use was associated with a significantly increased risk of fracture (relative risk, RR, 1.72; 95% CI [1.51, 1.95]; P<0.001). An increased fracture risk associated with SSRIs also was observed in the three studies that adjusted for bone mineral density (RR, 1.70; 95% CI [1.28, 2.25]; P<0.001) and in the four studies that adjusted for depression (RR 1.74; 95% CI [1.28, 2.36]; P<0.001). SSRI use was not associated with bone loss in the two cohort studies of women (P=0.29). The overall association between SSRI use and fracture risk was weaker (RR, 1.40; 95% CI [1.22, 1.61]), though still significant (P<0.001) in analyses that accounted for apparent publication bias. Conclusions Use of SSRIs is associated with increased risk of fracture. The SSRIs may exert an increased risk of fracture independent of depression and bone mineral density.
AB - Summary Studies on use of selective serotonin reuptake inhibitors (SSRIs) and risk of fracture have yielded inconsistent results. This meta-analysis, which pooled results from 13 qualifying cohort and case-control studies, found that SSRIs were associated with a significantly increased risk of fractures. Introduction This study was conducted to assess whether people who take SSRIs are at an increased risk of fracture. Methods We conducted a meta-analysis of observational studies. Relevant studies published by February 2010 were identified through literature searches using MEDLINE (from 1966), EMBASE (from 1988), PsycINFO (from 1806), and manual searching of reference lists. Only cohort or case-control studies that examined the association of SSRIs and risk of fracture and bone loss were included. Data were abstracted independently by two investigators using a standardized protocol; disagreements were resolved by consensus. Random effects models were used for pooled analysis due to heterogeneity in the studies. Results Thirteen studies met inclusion criteria. Overall, SSRI use was associated with a significantly increased risk of fracture (relative risk, RR, 1.72; 95% CI [1.51, 1.95]; P<0.001). An increased fracture risk associated with SSRIs also was observed in the three studies that adjusted for bone mineral density (RR, 1.70; 95% CI [1.28, 2.25]; P<0.001) and in the four studies that adjusted for depression (RR 1.74; 95% CI [1.28, 2.36]; P<0.001). SSRI use was not associated with bone loss in the two cohort studies of women (P=0.29). The overall association between SSRI use and fracture risk was weaker (RR, 1.40; 95% CI [1.22, 1.61]), though still significant (P<0.001) in analyses that accounted for apparent publication bias. Conclusions Use of SSRIs is associated with increased risk of fracture. The SSRIs may exert an increased risk of fracture independent of depression and bone mineral density.
KW - Antidepressant
KW - Bone fractures
KW - Bone mineral density
KW - Depression . Osteoporosis
KW - Serotonin reuptake inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84857370715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857370715&partnerID=8YFLogxK
U2 - 10.1007/s00198-011-1778-8
DO - 10.1007/s00198-011-1778-8
M3 - Article
C2 - 21904950
AN - SCOPUS:84857370715
SN - 0937-941X
VL - 23
SP - 365
EP - 375
JO - Osteoporosis International
JF - Osteoporosis International
IS - 1
ER -